2004
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
Tay M, Kaufman D, Regan M, Leibowitz S, George D, Febbo P, Manola J, Smith M, Kaplan I, Kantoff P, Oh W. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals Of Oncology 2004, 15: 974-978. PMID: 15151957, DOI: 10.1093/annonc/mdh221.Peer-Reviewed Original ResearchConceptsProstate-specific antigen nadirProstate-specific antigenSerum prostate-specific antigenAdvanced prostate cancerProstate cancerSexual functionMedian decreaseMedian time to treatment failureTime to treatment failurePrimary hormonal therapyMedian Follow-UpAndrogen blockadeAdvanced adenocarcinomaHormone therapyTreatment failureSpontaneous erectionsToxic therapiesMedian timeFollow-upDisease progressionFinasterideSide effectsBicalutamidePatientsSurgical castration
2001
Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up
Gilligan T, Oh W. Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up. The Prostate Journal 2001, 3: 42-43. DOI: 10.1046/j.1525-1411.2001.003001042.x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply